{"id":"W2955874948","doi":"10.1016/s1474-4422(19)30137-1","title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Acorda Therapeutics; Celgene; Biogen","keywords":"Placebo; Multiple sclerosis; Medicine; Phase (matter); Internal medicine; Physical therapy; Alternative medicine; Psychiatry; Chemistry; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007880374,0.000189897,0.001334559,0.0001305603,0.00006994749,0.000009193046,0.0001584638,0.0000850815,0.00004996053],"category_scores_gemma":[0.001534586,0.0001064931,0.00008479651,0.0001776199,0.0002555376,0.00004868652,0.0001263487,0.0004346349,0.000007226002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002169332,"about_ca_system_score_gemma":0.00004507177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007252131,"about_ca_topic_score_gemma":0.00005181037,"domain_scores_codex":[0.9979179,0.0005133101,0.0004737406,0.0003432443,0.0003185631,0.0004332352],"domain_scores_gemma":[0.9965513,0.002606795,0.0001976229,0.0004899096,0.00008330603,0.00007111501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9096599,0.000519179,0.08424691,0.00003941046,0.000153744,0.00000411766,0.0002880926,0.00009525251,0.001279559,0.00001846087,0.00007636648,0.003619021],"study_design_scores_gemma":[0.7359056,0.003650956,0.2588326,0.00007167056,0.00005774328,0.000001835925,0.00001245156,0.001114864,0.00005619887,0.000004493737,0.0002217747,0.00006981197],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992569,0.0001428259,0.00001649278,0.001859612,0.0001524095,0.00465971,0.00001560833,0.0000249327,0.0005593944],"genre_scores_gemma":[0.9988612,0.0003040003,0.00006002956,0.0004483838,0.0001415588,0.00009418179,0.00001040255,0.00002328832,0.00005696225],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1745857,"threshold_uncertainty_score":0.4342664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03542653499353299,"score_gpt":0.2888135071652921,"score_spread":0.2533869721717591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}